Seeking Alpha

dougout

dougout
Send Message
View as an RSS Feed
View dougout's Comments BY TICKER:
Latest  |  Highest rated
  • First Solar Q4 Financials, 2012 Guidance: Challenges Ahead [View article]
    Eric, you mentioned the product failure problem and I've heard about it from several analysts. It would be a great service to readers (as well as FSLR) if you could get a handle on how serious this problem is. Is $100 million a huge, awful, portentous number that will take FSLR and CdTe and all thin films down, or is it an acceptable cost of doing business for a $3+ billion company?

    Thanks.

    The presentation for the quarterly report (page 11 here: http://bit.ly/yz8UGW) says the following:

    Warranty and related charges breakdown
    Manufacturing Excursion related charges:
    Costs to remove and replace modules $23.9M (Q4) $99.7M (YTD)
    Power loss compensation $31.8M (Q4) $45.9M (YTD)
    Costs for replaced modules $70.1M (Q4) $70.1M (YTD)
    Total Manufacturing Excursion related charges $125.8M (Q4) $215.7M (YTD)
    Feb 29, 2012. 07:13 PM | Likes Like |Link to Comment
  • Dendreon: Fear is Our Friend [View instapost]
    Thank you Saul for so eloquently spreading the truth about Dendreon and Provenge!
    Jul 8, 2010. 11:56 AM | 1 Like Like |Link to Comment
  • No New News on Negative Rates from Bank of England’s Meeting Minutes [View article]
    Dr. Duru, I just wanted to thank you for your posts. I'm very interested in solar, so this BoE assessment is gravy. Thanks.
    Sep 23, 2009. 01:08 PM | Likes Like |Link to Comment
  • Dendreon Troubles Beyond Provenge Test [View article]
    Read walldiver's comment above! It is accurate, and brings the Provenge story home.
    Apr 16, 2009. 08:28 AM | 6 Likes Like |Link to Comment
  • Dendreon Gets Another Analyst Thumbs-Down [View article]
    Mike, please remember who's really taking it on the chin when another analyst piles on against Provenge's prospects. It's not you. The primary victims are the people with prostate cancer and their families and friends, who would prefer access to a breakthrough cancer therapy that almost certainly works (the remaining question is to what extent it works), is certainly safe, and has no significant side effects. Secondary victims are those with cancers other than prostate, that Dendreon is working on, who must wait much longer for their immunotherapies, because of the costly delays in getting Provenge approved. The third set of victims, admittedly far less penalized than the medical victims, because "it's only money," are the Dendreon shareholders. Every investor must accept the possibility of an investment gone bad, but it's frustrating how the plague of naked short selling, artificial "management" of the stock through gigantic option open interest, and extensive and documented financial conflicts of interest within the FDA and a few of its consultants, have all combined to keep the financial benefits limited to the short sellers and short-term traders.

    How to crush innovation and hope? Just watch what's going on at the FDA and in the stock market, with Dendreon. How to help? Don't whine about taking it on the chin. Instead, present the truth, and keep presenting it. Give your readers the links to the conference call announcing the interim results, which shows Provenge works, and that based on similarities between this and previous trials, the odds are better than 50/50 that it will be approved in mid-2009. Give them the history, showing how the FDA took the unprecedented step of going against its own advisory committee, to deny approval of Provenge, and how the FDA commissioner made great speeches about the golden future of individualized immunotherapy, and then proceeded to allow it to be stomped on. Tell them about the 30-million share short interest in DNDN. In other words, Mike, give your readers the amazing context surrounding Dendreon medicine and finances. I know you can do this. You have in the past, and we hope you will now and in the future. Thanks.
    Oct 17, 2008. 09:46 AM | 1 Like Like |Link to Comment
  • Dendreon: The FDA's Commissioner Doth Protest Too Much! [View article]
    Thank you, Dr. Cohen for your article. Thank you, BSR_David and others for your comments and rebuttals to "Been There." Shame on those in leadership positions at the FDA who continue to betray those they're entrusted to help.
    Apr 21, 2008. 08:39 PM | Likes Like |Link to Comment
  • After a Devastating Trading Loss [View article]
    Brett, thanks a lot for this article. Having just had my own version of your 1982, it is very very relevant. You didn't need to share this personal history, and I appreciate that you did.
    Nov 28, 2007. 12:12 AM | Likes Like |Link to Comment
  • The Power of the Apple iPhone: Will People Switch to AT&T Just to Get One? [View article]
    Chad,

    Your question is a good one. I switched from Verizon to AT&T/Cingular specifically for the iPhone. I got AT&T's cheapest phone (until I can switch it for the iPhone) and so far reception is better and, unlike Verizon, no calls have been dropped.

    mckalias
    Jun 11, 2007. 04:39 PM | Likes Like |Link to Comment
  • Dead Wrong, And Even With the Market [View article]
    Roger, Jim Cramer maintains a charitable trust "ActionAlertsPlus." I am a subscriber. The portfolio of 20-25 stocks is up 6.34% YTD as of today. In fairness Cramer has many rules constraining his actions with these stocks, such as not being able to trade them for 5 days after they're mentioned on his TV show, etc.

    My approach has been exactly as your has been: incorrectly bearish for a while now, but not so arrogant as to have bet the farm on my theories. I suppose the bear will stay hibernating as long as the blizzard of money continues to fall. Thanks for this and your other articles.
    Dec 11, 2006. 07:36 PM | Likes Like |Link to Comment
COMMENTS STATS
9 Comments
8 Likes